Physician group Cellular Medicine Association stated on Monday that the US FDA has approved the use of the plasma (convalescent plasma) from the survivors of COVID-19 to be given as a life-saving treatment to those who may still be fighting to survive acute COVID-19 infection.
Cellular Medicine Association said people who survive COVID-19 harbor antibodies in their blood that fought the virus and won. Physicians struggle to quickly find the blood of a local person who has survived COVID-19 and who can donate the life-saving convalescent plasma, but the survivors do not know where to go to donate their blood.
The organisation has built a website, COVID19Switchboard.org, that connects those looking for blood and those wanting to give blood. This free switchboard works in every country (using Google Translate).
About 2000 company physicians and nurse practitioners in over 50 countries focus on connect potential donors with physicians through the procedures invented by Dr Runels--the Vampire Facelift, the Vampire Facial, the O-Shot and the Priapus Shot.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach